Core Insights - Tencent Holdings (00700), Southern Hang Seng Technology (03033), and Xiaomi Group-W (01810) ranked as the top three in net inflow of southbound funds, with net inflows of 1.792 billion, 0.571 billion, and 0.412 billion respectively [1] - The top three in net outflow of southbound funds were Yingfu Fund (02800), Hang Seng China Enterprises (02828), and Kuaishou-W (01024), with net outflows of -4.553 billion, -1.380 billion, and -0.576 billion respectively [1] - In terms of net inflow ratio, Huaxia Hang Seng Technology (03088), Southern East Selection (03441), and Anhui Wantuo Expressway (00995) led the market with ratios of 90.53%, 74.02%, and 68.27% respectively [1] - The top three in net outflow ratio were Southern Hong Kong Stock Connect (03432), Fuyao Glass (06865), and Baize Medical (02609) with ratios of -100.00%, -59.27%, and -53.09% respectively [1] Net Inflow Rankings - Tencent Holdings (00700) had a net inflow of 1.792 billion, representing a 12.21% increase, closing at 560.000 (+2.28%) [2] - Southern Hang Seng Technology (03033) saw a net inflow of 0.571 billion, with a 6.77% increase, closing at 5.300 (+1.34%) [2] - Xiaomi Group-W (01810) recorded a net inflow of 0.412 billion, with a 9.45% increase, closing at 35.200 (+0.06%) [2] Net Outflow Rankings - Yingfu Fund (02800) experienced the highest net outflow of -4.553 billion, with a -22.13% decrease, closing at 27.220 (+1.72%) [2] - Hang Seng China Enterprises (02828) had a net outflow of -1.380 billion, representing an -11.37% decrease, closing at 93.940 (+1.56%) [2] - Kuaishou-W (01024) faced a net outflow of -0.576 billion, with a -10.25% decrease, closing at 69.300 (-2.74%) [2] Net Inflow Ratio Rankings - Huaxia Hang Seng Technology (03088) led with a net inflow ratio of 90.53%, with a net inflow of 47.6883 million, closing at 6.875 (+1.33%) [3] - Southern East Selection (03441) followed with a net inflow ratio of 74.02%, with a net inflow of 18.0421 million, closing at 11.600 (+1.13%) [3] - Anhui Wantuo Expressway (00995) had a net inflow ratio of 68.27%, with a net inflow of 5.6553 million, closing at 13.340 (-0.07%) [3]

证券日报网讯 2月10日，新华制药在互动平台回答投资者提问时表示，公司始终致力于心无旁骛发展医 药主业，努力为各利益相关方创造更多回报。 （文章来源：证券日报） ...

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration certificate of Glucosamine Sulfate Capsules, which are primarily used for the treatment of primary and secondary osteoarthritis [1] Company Summary - Xinhua Pharmaceutical has successfully obtained the necessary regulatory approval for its Glucosamine Sulfate Capsules, indicating a significant step in expanding its product offerings in the pharmaceutical market [1]

Core Viewpoint - Xinhua Pharmaceutical has received approval from the National Medical Products Administration for the registration of glucosamine sulfate capsule, which is classified as a Class 4 chemical drug and a Class A non-prescription drug, aimed at treating primary and secondary osteoarthritis [1] Group 1 - The glucosamine sulfate capsule is available in specifications of 0.25g or 0.314g [1] - The drug has been included in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2025) as a Category B product [1]

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration certificate of Glucosamine Sulfate Capsules, which are primarily used for the treatment of primary and secondary osteoarthritis [1] Group 1 - The approval signifies a regulatory milestone for the company, enhancing its product portfolio in the pharmaceutical market [1] - Glucosamine Sulfate Capsules are aimed at addressing a significant medical need in the treatment of osteoarthritis, a common joint disorder [1]

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration certificate of Glucosamine Sulfate Capsules, which are primarily used for the treatment of primary and secondary osteoarthritis [1] Company Summary - The approval of Glucosamine Sulfate Capsules marks a significant milestone for Xinhua Pharmaceutical, enhancing its product portfolio in the orthopedic treatment sector [1] - The clinical application of this product targets a growing market for osteoarthritis treatments, indicating potential revenue growth for the company [1] Industry Summary - The approval aligns with the increasing demand for effective treatments for osteoarthritis, a condition affecting a large segment of the population [1] - The pharmaceutical industry is witnessing a trend towards the development of specialized medications for chronic conditions, which may lead to increased competition and innovation in the market [1]

证券代码：000756 证券简称：新华制药 公告编号：2026-04 山东新华制药股份有限公司 关于获得硫酸氨基葡萄糖胶囊药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或 重大遗漏。 近日，山东新华制药股份有限公司（以下简称"新华制药"或"本公司"）收到国家药品监督管理 局核准签发的硫酸氨基葡萄糖胶囊（以下简称"本品"）《药品注册证书》。现将相关情况公告如下： 一、基本情况 药品名称：硫酸氨基葡萄糖胶囊 剂型：胶囊剂 规格：0.25g（按硫酸氨基葡萄糖计）或0.314g（按硫酸氨基葡萄糖氯化钠计） 药品分类：非处方药 注册分类：化学药品4类 申请人：山东新华制药股份有限公司 申请事项：药品注册（境内生产） 受理号：CYHS2402615 药品批准文号：国药准字H20263303 证书编号：2026S00360 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注册的有关 要求，批准注册，发给药品注册证书。同意本品按（甲类）非处方药管理。质量标准、说明书、标签 及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求方可生 ...

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration of Glucosamine Sulfate Capsules, which are primarily used for treating primary and secondary osteoarthritis [1] Group 1: Product Approval - The approval of Glucosamine Sulfate Capsules enhances the company's formulation product portfolio [1] - This product is classified as a Category B item in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2025) [1] Group 2: Market Potential - The estimated sales revenue for Glucosamine Sulfate Capsules in Chinese public medical institutions is approximately RMB 850 million in 2024 [1] - The introduction of this product is expected to improve the company's overall competitiveness in the market [1] Group 3: Industry Considerations - The pharmaceutical sales business is subject to uncertainties influenced by industry policies and market conditions [1]

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of Glucosamine Sulfate Capsules, which are primarily used for the treatment of primary and secondary osteoarthritis [1] Company Summary - The company has announced the receipt of a drug registration certificate for Glucosamine Sulfate Capsules [1] - The clinical application of the product focuses on treating osteoarthritis, indicating a strategic move into the growing market for joint health [1]

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of Glucosamine Sulfate Capsules, which are primarily used for treating primary and secondary osteoarthritis [1] Company Summary - The company submitted the application for the marketing authorization of Glucosamine Sulfate Capsules to the National Medical Products Administration in August 2024, and the application was accepted [1] - The drug received its registration certificate in February 2026, with the review conclusion being approval for registration [1] Industry Summary - Glucosamine Sulfate Capsules are classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025) [1] - The sales revenue for Glucosamine Sulfate Capsules in Chinese public medical institutions is estimated to be approximately RMB 850 million in 2024 [1]